Regemat 3D Seeks 1.5 Million to Accelerate in Bioprinting

Regemat 3D is in search of more capital, to continue growing. The company from Granada that manufactures tissue and organ biofabrication systems is seeking $1.7 million (€1.5 million) to continue advancing in this sector and to be able to go public in the next few years, according to Manuel Figueruela, CEO of Regemat 3D, as he explained to PlantaDoce.

To make this a reality, the Spanish company is opening a round of financing via crowdfunding through Crowdcube and expects to complete the remaining amount to reach $1.7 million (€1.5 million) through “loans for research and development (R&D) projects,” says Figueruela.

The company started with a first investment of $114,000 (€100,000), by the end of 2020 it raised more than $514,000 (€450,000) and is now opening this third round through the British-based platform.

Read more about Regemat 3D and its bioprinting technology and read the most important business headlines of the day with the Born2Invest mobile app.

Regemat 3D has the REG4Life bioprinter and a bioreactor to manufacture articular cartilage

Based in Granada, Regemat 3D is one of the main players in this new industry. The company manufactures tissue and organ biofabrication systems, bioprinters, and bioreactors, which researchers use to try to find solutions to tissue injuries in tissues such as cartilage, bone, spinal cord, and muscle tissue, among others.

With Regemat 3D’s 2020 round of funding, the company increased revenue, brought out a new bioprinter, REG4Life, and fine-tuned a bioreactor to make articular cartilage.

The company also launched the labmethods.org platform where researchers from around the world will share their tissue manufacturing methods in a way that will accelerate the development of solutions in the area. “It’s like a recipe website where researchers find descriptions of how to make a particular fabric, and they can access to buy all the necessary ingredients easily and quickly,” explains José Manuel Baena, founder of the company.

Regemat 3D was founded in 2015 and is located in the Granada Health Technology Park. The company was born out of another company, Breca Health Care, which was founded in 2011, and which specializes in 3D printing of medical devices. Regemat 3D emerged as a project focused on cartilage cells.

The 3D bioprinting market will reach a value of $1.647 billion by 2024, according to a study by Markets and Markets. The large number of tissue pathologies resulting from aging and the need to speed up the development of new drugs and reduce the use of animals for research make 3D bioprinting a sector that is gaining a lot of interest in the research and scientific field.

__

(Featured image by UC San Diego Jacobs School of Engineering CC BY 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.